A phase II, placebo controlled, double-blind, randomized, discontinuation study of lapatinib administered orally to subjects with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancer.

Trial Profile

A phase II, placebo controlled, double-blind, randomized, discontinuation study of lapatinib administered orally to subjects with ErbB2 positive ovarian, gastric/esophageal adenocarcinoma, uterine serous papillary, or bladder cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2012

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Bladder cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Uterine cancer
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jan 2010 Actual initiation date changed from Jan 2007 to May 2007 as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Planned end date changed from 1 Oct 2010 to 1 Sep 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top